MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too

13th July 2018 Uncategorised 0

A ruling from the U.S. Patent and Trademark Office pushes Novartis’ exclusivity on Gilenya from 2019 to 2027. That will give Celgene more time to secure FDA approval for its Gilenya rival and persuade physicians that it’s a safer alternative to Novartis’ multiple sclerosis blockbuster.

More: MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
Source: fierce